Hives, also called urticaria, are red, itchy welts that can appear anywhere on the body and range from mild to severe. In ...

P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double-Blind, Randomized, ...

Urticaria affects 10% to 25% of the population at some point in their life (Henderson, Fleischer, & Feldman, 2000). It is characterized by short-lived swellings of the skin, mouth, and genitalia ...

An allergic reaction in babies can range from mild to life-threatening. Here’s how to tell if your child is having an ...

Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 ...

Analyst Etzer Darout from BMO Capital reiterated a Buy rating on Jasper Therapeutics (JSPR – Research Report) and keeping the price target at ...

Omalizumab biosimilar is under clinical development by Mabpharm and currently in Phase III for Chronic Urticaria Or Hives. According ...

Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profileMean change in UAS7 ...

Sanofi and Regeneron have reported disappointing results in a trial of Dupixent in people with chronic spontaneous urticaria (CSU) who don't respond to the only approved biologic treatment ...

INF-904 is under clinical development by InflaRx and currently in Phase I for Chronic Urticaria Or Hives. According to GlobalData, Phase I drugs for Chronic Urticaria Or Hives have an 87% phase ...